37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor β/δ (NR1C2) Antagonist

      other

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The identification of small molecule ligands for the peroxisome proliferator-activated receptors (PPARs) has been instrumental in elucidating their biological roles. In particular, agonists have been the focus of much of the research in the field with relatively few antagonists being described and all of those being selective for PPARα or PPARγ. The comparison of these agonist and antagonist ligands in cellular and animal systems has often led to surprising results and new insights into the biology of the PPARs. The PPARβ/δ receptor is emerging as an important regulator of energy metabolism, inflammation, and cell growth and differentiation; however, only agonist ligands have been described for this receptor thus far. Here we describe the first report of a PPARβ/δ small molecule antagonist ligand. This antagonist ligand will be a useful tool for elucidating the biological roles of PPARβ/δ.

          Related collections

          Author and article information

          Journal
          Mol Endocrinol
          Mol. Endocrinol
          mend
          Molecular Endocrinology
          Endocrine Society
          0888-8809
          1944-9917
          February 1, 2008
          : 22
          : 2
          : 523-529
          Affiliations
          GlaxoSmithKline (B.G.S., J.M.W., T.B.S., D.C.L., M.A.I., T.M.W., A.N.B.), Research and Development, Research Triangle Park, North Carolina 27709; GlaxoSmithKline (D.A.G.), Research and Development, 91951 Les Ulis, France; and Division of Endocrinology, Diabetes, and Metabolism (D.J.S., M.A.L.), Department of Medicine, The Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
          Author notes
          Address all correspondence and requests for reprints to: Andrew N. Billin, GlaxoSmithKline, Research and Development, Research Triangle Park, North Carolina 27709. E-mail: andrew.n.billin@ 123456GSK.com .
          Article
          PMC5419638 PMC5419638 5419638 4186
          10.1210/me.2007-0190
          5419638
          17975020
          684f3e15-8265-4b71-87e7-e092eccd5dab
          Copyright @ 2008
          History
          : 15 October 2007
          : 16 April 2007
          Categories
          Articles
          Custom metadata
          523
          Research Resource

          Comments

          Comment on this article

          scite_
          0
          0
          0
          0
          Smart Citations
          0
          0
          0
          0
          Citing PublicationsSupportingMentioningContrasting
          View Citations

          See how this article has been cited at scite.ai

          scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

          Similar content219

          Cited by34